转化医学(from Bench to Bedside)
健康数据(Big Health Data)
台湾竹北生医园区筹备运营处 2001-2004 副主任
厦门佰香汇/芮宝生技公司 2010-2016 创始人
扬州市国家高科区技术与招商顾问 2015- Present技术与招商顾问
1: Huang WQ, Lu CX, Zhang Y, Yi KH, Cai LL, Li ML, Wang H, Lin Q, Tzeng* CM. A Novel CCM2 Gene Mutation Associated with Familial Cerebral Cavernous
Malformation. Front Aging Neurosci. 2016 Sep 21;8:220.
2: Cai LL, Liu GY, Tzeng* CM. Genome-wide DNA methylation profiling and itsinvolved molecular pathways from one individual with thyroid malignant/benigntumor and hyperplasia. Medicine. 2016Aug;95(35):e4695.
3: Huang WQ, Ye HM, Li FF, Yi KH, Zhang Y, Cai LL, Lin HN, Lin Q, Tzeng* CM.Analysis of genetic polymorphisms associated with leukoaraiosis in the southernChinese population. Medicine. 2016Aug;95(35):e3857.
4: Li Z, Zheng Z, Ruan J, Li Z, Zhuang X, Tzeng* CM. Integrated analysis miRNA andmRNA profiling in patients with severe oligozoospermia reveals miR-34c-3pdownregulates PLCXD3 expression. Oncotarget. 2016 Aug 16;7(33):52781-52796.
5: Li Z, Zheng Z, Ruan J, Li Z, Tzeng* CM. Chronic Inflammation Links Cancer andParkinson's Disease. Front Aging Neurosci. 2016 Jun 3;8:126.
6: Zhan L, Pan YZ, Chen L, Zhang H, Zhang H, Song J, Tzeng* CM, Sun CY. Prevalenceof ABCB4 polymorphisms in gallstone disease in han-Chinese population. Am JTransl Res. 2016 Feb 15;8(2):1218-27.
7: Hu P, Hsieh MH, Lei MJ, Cui B, Chiu SK, Tzeng* CM. A Simple Algorithm forPopulation Classification. Nature: Sci Rep. 2016 Mar 31;6:23491.
8: Li Z, Lin H, Gu L, Gao J, Tzeng* CM. Herba Cistanche (Rou Cong-Rong): One ofthe Best Pharmaceutical Gifts of Traditional Chinese Medicine. Front Pharmacol.2016 Mar 1;7:41.
9: Hu P, Han DX, Ruan RS, Zheng LM, Chou SH, Tzeng* CM. Transtinib, a potenttyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines andxenografts. Oncotarget. 2016 Jun 14;7(24):35741-35752.
10: Li Z, Zhong L, Gu L, Huang W, Shi X, Zhang X, An X, Lin Q, Tzeng* CM.Association study of TREM2 polymorphism rs75932628 with leucoaraiosis orParkinson's disease in the Han Chinese population. BMJ Open. 2016 Jan12;6(1):e009499.
11: Lin Q, Huang WQ, Tzeng* CM. Corrigendum to: Genetic associations ofleukoaraiosis indicate pathophysiological mechanisms in white matter lesionsetiology. Rev Neurosci. 2015;26(5):607-8.
12: Li Z, Lin Q, Huang W, Tzeng* CM. Target gene capture sequencing in Chinesepopulation of sporadic Parkinson disease. Medicine. 2015May;94(20):e836.
13: Lin Q, Huang WQ, Tzeng* CM. Genetic associations of leukoaraiosis indicatepathophysiological mechanisms in white matter lesions etiology. Rev Neurosci. 2015;26(3):343-58.
14: Zhuang X, Li Z, Lin H, Gu L, Lin Q, Lu Z, Tzeng* CM. Integrated miRNA and mRNAexpression profiling to identify mRNA targets of dysregulated miRNAs innon-obstructive azoospermia. Nature: Sci Rep. 2015 Jan 28;5:7922.
15: Sun C, Yan G, Li Z, Tzeng* CM. A meta-analysis of the effect of preoperativebiliary stenting on patients with obstructive jaundice. Medicine.2014 Nov;93(26):e189.
16: Cai LL, Ye HM, Zheng LM, Ruan RS, Tzeng* CM. Circulating tumor cells (CTCs) asa liquid biopsy material and drug target. Curr Drug Targets. 2014;15(10):965-72.
17: Huang S, Shen H, Li Z, Chiu SK, Ruan R, Xiao L, Tzeng* CM. Identification ofVβ7.1_H3F7 as a therapeutic gene encoding TCR specific to hepatocellularcarcinoma. Curr Gene Ther. 2014;14(5):389-99.
18: Huang WQ, Lin Q, Zhuang X, Cai LL, Ruan RS, Lu ZX, Tzeng* CM. Structure,function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis. Curr Cancer Drug Targets. 2014;14(6):567-88.
19: Lu CX, Qing Lin, Huang WQ, Tzeng* CM. New mutations and polymorphisms of theATP7B gene in sporadic Wilson disease. Eur J Med Genet. 2014 Sep;57(9):498-502.
20: Ye HM, Lu YZ, Liang XM, Lin YZ, Li Y, Zhang ZY, Tzeng* CM. Clinicalsignificance of combined testing of YKL-40 with CEA in Chinese colorectal cancer patients. Clin Lab. 2014;60(3):397-405.
21: Li Z, Lin Q, Ma Q, Lu C, Tzeng* CM. Genetic predisposition to Parkinson's disease and cancer. Curr Cancer Drug Targets. 2014;14(3):310-21.
22: Wang YQ, Song JJ, Han X, Liu YY, Wang XH, Li ZM, Tzeng* CM. Effects of angiopoietin-1 on inflammatory injury in endothelial progenitor cells and blood vessels. Curr Gene Ther. 2014;14(2):128-35.
23: Cai LL, Ye HM, Lv XN, Wu YL, Zhang HJ, Zheng LM, Tzeng* CM. 25-(OH)VitD3, as a risk indicator in diagnosis of adenocarcinoma. Curr Drug Targets. 2013 Oct;14(11):1367-76.
24: Ma Q, An X, Li Z, Zhang H, Huang W, Cai L, Hu P, Lin Q, Tzeng* CM. P268S in NOD2 associates with susceptibility to Parkinson's disease in Chinese population.Behav Brain Funct. 2013 May 7;9:19.
25: Lv XN, Liu ZJ, Zhang HJ, Tzeng* CM. Aromatherapy and the central nerve system (CNS): therapeutic mechanism and its associated genes. Curr Drug Targets. 2013Jul;14(8):872-9.
Dr. Tzeng received comprehensively graduated training from National Tsin-Hua University (NTHU, School of Nuclear Sciences in Radiation Biology, advised by Dr. Rong-Long Pan, in 1989~1993) and Stanford University (Medical School in Immunology/ Biochemistry, advised by Drs. Peter Parham/Arthur Kornberg, Nobel Prize Laureate, in 1995~1999). Moreover, he also expansively practiced either in academic or in industrial executive position from Academic Sinica (Instit. of BioAgricultural Science), National Taiwan University Hospital (Department of Biomedical Research), U-Vision Biotech, VitaGenomics/GeneCore, SBC/MaxyBio to Beckman Coulter since 2000 to 2010.
Dr. Tzeng possesses entirely skills of protein chemistry/biochemistry, -omics, translation medicine and Clinical Theranostics, holding more than 60 peer-reviewed SCI/IE publication, 6 book chapters, 4 PCT/9 the Greater China patents and in excess of 9 commercialized diagnostic products and 2 healthcare management program. He is interesting in pooling biomedical research, marketing analysis, intellectual properties, financial manipulation, manufacturing SOPs/QC/A and entrepreneur atmosphere together to cash out clinical/biomedical commercialization.
Dr. Tzeng is recently leading clinical resources, academic force and biopharmaceutical-industrial energy to decipher the biomarkers, drug target and personalized medicine from projects of adenocarcinoma (T-cell Theranostics), regenerative medicine (MSC theranostics), neuro-degradation (Leukoaraiosis and aromatherapy) and e-Healthcare solution (cancer, neurodegeneration, chronic disease management) at Xiamen University, Xiamen Torch Hi-Tech Industrial Development zone and Yangzhou Hi-Tech Industrial Park.